METHODS FOR COPY NUMBER DETERMINATION
The invention generally relates to a method for determining carrier or disease status with respect to a particular disease or condition. In certain embodiments, methods of the invention involve obtaining a sample including nucleic acid from a subject. The nucleic acid includes a genomic locus that is diagnostic for an autosomal recessive disease. The nucleic acid is captured and isolated from the sample and further sequenced. The method further includes analyzing sequence reads to determine a copy number of the captured nucleic acid and further determine a disease status based upon the copy number.
1 . A method for determining carrier status of an autosomal recessive disease, the method comprising the steps of:
capturing, using non-naturally occurring synthesized molecular inversion probes, nucleic acid corresponding to at least one genomic locus that is linked to a genomic locus that is diagnostic for an autosomal recessive disease;
sequencing, using a sequencing instrument, said captured nucleic acid;
determining copy number of said captured nucleic acid; and
determining disease status based upon said copy number.
2 . The method of claim 1 , wherein said autosomal recessive disease is spinal muscular atrophy.
3 . The method of claim 2 , wherein said at least one genomic locus is on intron 7 of an SMN1 or SMN2 gene or both.
4 . The method of claim 3 , wherein said genomic locus that is diagnostic for an autosomal recessive disease is on exon 7 of an SMN1 gene.
5 . The method of claim 4 , wherein said at least one genomic locus is selected from rs212214 and rs212213.
6 . The method of claim 1 , wherein said sequencing step comprises a Sanger sequencing method or a next-generation sequencing method.
7 . The method of claim 1 , wherein said capturing step comprises isolating said nucleic acid from a sample comprising nucleic acid from a subject.
8 . The method of claim 7 , wherein said sample is a maternal blood sample.
9 . The method of claim 8 , wherein said maternal blood sample comprises cell free circulating nucleic acid.
10 . The method of claim 9 , wherein at least a portion of the cell free circulating nucleic acid is from a fetus being carried within the subject.